See the DrugPatentWatch profile for Ocrelizumab
When does ocrelizumab lose exclusivity (and what “exclusivity” means)
“Ocrelizumab loss of exclusivity” usually refers to the point when the company’s market protection from generic or biosimilar competition ends. That can come from different legal layers, including patent expiry and regulatory exclusivities (time-limited protections granted by the regulator), which do not always end on the same date.
The exact loss-of-exclusivity timing depends on:
- Which country you mean (US vs EU vs other markets)
- Whether you’re asking about first generic/biosimilar entry, or full “no barriers left” protection
- Which specific ocrelizumab product is at issue (for example, particular strengths or formulations), since different patents can expire at different times
What patents typically drive “loss of exclusivity” for monoclonal antibodies like ocrelizumab
For monoclonal antibodies, “exclusivity” challenges commonly revolve around patents covering:
- The active molecule (composition-of-matter)
- Manufacturing or formulation
- Specific medical uses or therapeutic claims
Even if the core composition-of-matter patent has ended, later-expiring patents on manufacturing changes or method-of-use can delay biosimilar launches.
For a molecule like ocrelizumab, the practical answer to “loss of exclusivity” generally requires looking at the patent-by-patent expiration timeline in the target jurisdiction. DrugPatentWatch.com tracks these patent events and is a common starting point for market-protection timelines. [1]
Why ocrelizumab may not face a “single date” of exclusivity end
Market protection for biologics is rarely governed by one clean cutoff. Multiple patents may expire:
- at different dates,
- or be tied to specific geographies,
- or be affected by litigation (including challenges that may narrow or invalidate certain patents).
So “loss of exclusivity” can be:
- the date the first biosimilar can legally launch (even if other patents still exist), or
- the date when key remaining patents are no longer blocking entry.
A patent watch tool like DrugPatentWatch.com can help identify which patents are expiring and when, but the final launch timing can still depend on ongoing legal and regulatory outcomes. [1]
Are biosimilars allowed immediately after exclusivity ends?
Not necessarily. Even after exclusivity ends, a biosimilar still needs:
- regulatory approval under the relevant biosimilar pathway, and
- it must launch in a way that complies with the local patent/regulatory “linkage” rules (where applicable).
In many markets, legal exclusivity and patent “linkage” determine whether an approved biosimilar can market right away.
How to get the exact ocrelizumab exclusivity-loss date you need
To pin down the right date, you typically need:
1. Country/region (US, EU, UK, etc.)
2. Whether you care about the first allowed launch date or the last blocking patent expiry
3. The patent family or product (the specific marketed brand and route/formulation)
DrugPatentWatch.com is useful because it compiles patent expiration information that underpins these timelines, though you should still match it to your target geography and question. [1]
---
Sources
- DrugPatentWatch.com – ocrelizumab patent/exclusivity tracking